Evidence map›Paper›PMID 40675157›Full record

ReviewCell reports. Medicine2025

CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.

Leonard Knoedler, Konstantin Herfeld, Daniel A Schaefer, Fortunay Diatta, James Clune, Brogan Evans, Michelle Seu, Bong-Sung Kim, Michael Alfertshofer, Thomas Schaschinger and 11 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?International journal of molecular sciences · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Leonard KnoedlerDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Oral and Maxillofacial Surgery, Berlin, Germany; Division of Plastic and Reconstructive Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: leonard.knoedler@charite.de.
Konstantin HerfeldDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
Daniel A SchaeferDepartment of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
Fortunay DiattaDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA.
James CluneDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA.
Brogan EvansDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA.
Michelle SeuDepartment of Neurology, Loyola University Medical Center, Maywood, IL, USA.
Bong-Sung KimDepartment of Plastic Surgery and Hand Surgery, Zurich University Hospital, Zurich, Switzerland.
Michael AlfertshoferDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA.
Thomas SchaschingerDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA.
Jasper IskeDepartment of Cardiothoracic Surgery, Deutsches Herzzentrum der Charité, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Samuel KnoedlerDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA.
Alexandre G LellouchDivision of Plastic and Reconstructive Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Maxime JeljeliDivision of Plastic and Reconstructive Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Alberto CarturanCenter for Cellular Immunotherapies and Cellular Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Marco RuellaCenter for Cellular Immunotherapies and Cellular Therapy and Transplant, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Max HeilandCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Oral and Maxillofacial Surgery, Berlin, Germany.
Hendrik PoeckDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany; Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany.
Markus PerlDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany.
Bohdan PomahacDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA.
Martin Kauke-NavarroDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA. Electronic address: kauke-navarro.martin@yale.edu.

Funding

Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Joseph Anthony Fraietta · 2017 to 2026
$26.8M
MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCERR37CA262362 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Marco Ruella · 2022 to 2026
$2.6M
Selective B Cell Depletion Using Engineered T Cells As A Curative Treatment For Acquired Thrombotic Thrombocytopenic PurpuraR01HL178849 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Vijay Bhoj, Marco Ruella · 2025 to 2026
$1.6M
FDA HHS R01 FD008168NCI NIH HHS P01 CA214278NCI NIH HHS R37 CA262362NHLBI NIH HHS R01 HL178849
6 · The paper itself

Abstract

This review addresses the integration of chimeric antigen receptor (CAR)-T cell therapy with reconstructive oncologic surgery in treating peripheral solid tumors, including melanoma, sarcomas, breast cancer, and head and neck cancers. While CAR-T cells have demonstrated effectiveness in blood cancers, their efficacy in solid tumors has been limited due to tumor heterogeneity, immune suppression, and poor cellular infiltration. Emerging approaches involving localized CAR-T cell delivery, improved CAR design, and targeted antigen selection (such as HER2, MUC1, GD2, and B7-H3) are discussed as promising strategies to enhance therapeutic outcomes. Clinical studies highlighted in this review indicate improved local tumor control and potential to optimize surgical resections. Additionally, combining CAR-T therapy with surgery may reduce tumor recurrence and positively influence reconstructive outcomes. Overall, this review underscores CAR-T cell therapy as a potential adjunctive treatment in oncologic surgery, emphasizing the importance of interdisciplinary approaches to improve patient outcomes in solid tumor management.

Indexed as

Immunotherapy, AdoptiveNeoplasmsPlastic Surgery ProceduresReceptors, Chimeric AntigenHumansT-LymphocytesReceptors, Chimeric Antigenbreast cancerCAR-T cellschimeric antigen receptorclinical trialshead and neck cancerimmunotherapymalignant melanomareconstructive surgerysarcomaskin cancer

Identifiers

PMID40675157
PMCPMC12432357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.